Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis

NCT06716281 is registered in ClinicalTrials.gov with Shanghai IxCell Biotechnology Co., LTD as lead sponsor.

NCT NCT06716281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06716281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis
Lead sponsor
Shanghai IxCell Biotechnology Co., LTD
Phase
Phase 3
Overall status
Recruiting
Start date
January 5, 2024
Completion date
December 31, 2025
Enrollment
398 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

knee osteoarthritis